1 Newamsterdam Pharma Company N V Receivables Turnover Ratio (NAMS), from the second quarter 2026 to the second quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Newamsterdam Pharma Company N v   (NASDAQ: NAMS)
 

Newamsterdam Pharma N V Accounts Receivables Turnover Ratio from the second quarter 2026 to the second quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Newamsterdam Pharma Company N V 's ability to collect accounts receivable sequentially worsen to 1.2, indicating more challenging environment then in the first quarter 2026, but still, it is a far cry from any concerns. Newamsterdam Pharma N V 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 304 days, from 89 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 555 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 3230 to 3760.

What is Receivable Turnover Ratio?
What is Newamsterdam Pharma Company N V Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NAMS Receivables Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Receivable Change 55.37 % 455.83 % 287.01 % 136.88 % 54.12 %
Y / Y Revenue Change -80.67 % 2.08 % -99.75 % -98.8 % 740.06 %
Receivable Turnover Ratio (TTM) 1.2 4.11 5.85 13.58 31.51
NAMS's Total Ranking # 3760 # 3230 # 3305 # 2052 # 2906
Accounts Receivable average collection period days 305 89 62 27 12
Seq. Receivable Change -36.24 % 18.48 % 73.51 % 18.55 % 128.09 %
Seq. Revenue Change 21.74 % 9400 % -90.8 % -98.18 % 542.88 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 197
Healthcare Sector # 556
Overall Market # 3760

Receivable Turnover Ratio Statistics
High Average Low
0.09 0.05 0.01
(Jun 30 2025)   (Jun 30 2026)





NAMS Company Profile • Back to NAMS Efficiency Comparisons • Compare NAMS Receivables Turnover Ratio to its Competitors

Financial Statements
Newamsterdam Pharma N V 's Accounts Receivable $ 5 Millions Visit NAMS's Balance sheet
Newamsterdam Pharma N V 's Sales TTM $ 7 Millions Visit NAMS's Income Statement
Sources of NAMS's Revenues Visit NAMS's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
NAMS's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
NAMS's Growth Rates NAMS's Roa NAMS's Inventory Turnover Ratio NAMS's Dividend Comparisons
NAMS's Profitability Ratios NAMS's Roi NAMS's Asset Turnover Ratio NAMS's Dividend Growth
NAMS's Valuation Ratios NAMS's Roe NAMS's Financial Strength Ratios NAMS's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Receivable at quarter ending Jun 30 2026
Tonix Pharmaceuticals Holding Corp   3.83 $ 29.102  Millions$ 7.594  Millions
Urogen Pharma Ltd   3.82 $ 188.317  Millions$ 49.239  Millions
Akebia Therapeutics Inc   3.82 $ 219.060  Millions$ 57.324  Millions
Eyepoint Inc   3.79 $ 2.788  Millions$ 0.735  Millions
Alpha Cognition Inc.  3.78 $ 15.261  Millions$ 4.034  Millions
Biomarin Pharmaceutical Inc  3.72 $ 3,406.614  Millions$ 915.860  Millions
Biocorrx Inc   3.72 $ 0.787  Millions$ 0.211  Millions
Cytek Biosciences Inc   3.72 $ 205.086  Millions$ 55.186  Millions
Align Technology inc   3.70 $ 4,138.567  Millions$ 1,118.659  Millions
Ani Pharmaceuticals Inc  3.68 $ 978.379  Millions$ 265.900  Millions
Autolus Therapeutics Plc  3.65 $ 117.390  Millions$ 32.171  Millions
Vivosim Labs Inc   3.64 $ 0.112  Millions$ 0.031  Millions
Procept Biorobotics Corporation  3.62 $ 336.764  Millions$ 93.008  Millions
Evofem Biosciences Inc   3.61 $ 18.045  Millions$ 4.993  Millions
Adma Biologics Inc   3.58 $ 510.934  Millions$ 142.549  Millions
Ss Innovations International Inc  3.55 $ 52.199  Millions$ 14.717  Millions
Sensus Healthcare Inc   3.55 $ 18.294  Millions$ 5.159  Millions
Dyadic International Inc   3.50 $ 3.802  Millions$ 1.085  Millions
Abcellera Biologics Inc   3.44 $ 66.174  Millions$ 19.210  Millions
Ars Pharmaceuticals Inc   3.41 $ 116.927  Millions$ 34.325  Millions
Hyperfine Inc   3.40 $ 15.425  Millions$ 4.537  Millions
Lifeward ltd   3.38 $ 21.822  Millions$ 6.447  Millions
Krystal Biotech Inc   3.37 $ 440.484  Millions$ 130.686  Millions
Zymeworks Inc   3.33 $ 37.127  Millions$ 11.149  Millions
Arcutis Biotherapeutics Inc   3.31 $ 463.981  Millions$ 140.221  Millions
Axsome Therapeutics Inc   3.27 $ 776.569  Millions$ 237.373  Millions
Establishment Labs Holdings Inc   3.25 $ 245.105  Millions$ 75.416  Millions
Coherus Oncology inc   3.23 $ 50.936  Millions$ 15.751  Millions
Kyntra Bio Inc   3.23 $ 4.617  Millions$ 1.431  Millions
Collegium Pharmaceutical Inc   3.14 $ 751.744  Millions$ 239.785  Millions

Date modified: 2026-10-15T05:23:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.